MedPath

Multimodal MRI-guided rTMS to Treat Refractory Hallucinations

Not Applicable
Completed
Conditions
Hallucinations
Perceptual Disorders
Schizophrenia
Interventions
Device: MagPro X100 repetitive Transcranial Magnetic Stimulation
Registration Number
NCT01373866
Lead Sponsor
University Hospital, Lille
Brief Summary

* The efficacy of neuro-navigated rTMS for patients with schizophrenia suffering from drug-resistant multisensory hallucinations will be tested by the implementation of a double-blind randomized controlled trial (RCT)

* This study will use a combination of different MRI modalities (fMRI and DTI) to define with precision rTMS brain-targets in the case of multisensory hallucinations

* The investigators anticipate that multimodal MRI-guided rTMS will allow a significant improvement in the efficacy of neuromodulation treatment of refractory hallucinations

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
76
Inclusion Criteria
  • Right-handed Female/Male, [13-60 y.o.],
  • Schizophrenia (DSM-IV-TR diagnosis),
  • Drug-resistant hallucinations (Kinon & Kane criteria, 1993),
  • Unmodified antipsychotic dosage during the 30 days preceding rMTS,
  • No anticonvulsive medication,
  • No neurological disorder, no addictive behavior,
  • Matched for sex, age and PANSS scores,
  • Consent to participate to the study,
Exclusion Criteria
  • Pregnancy
  • Contraindication to MRI scan
  • Contraindication to rTMS treatment
  • Claustrophobia
  • No social insurance

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Conventional T3-P3 rTMSMagPro X100 repetitive Transcranial Magnetic Stimulation-
Multimodal MRI-guided rTMSMagPro X100 repetitive Transcranial Magnetic Stimulation-
Primary Outcome Measures
NameTimeMethod
Severity and Frequency of HallucinationsAssessed at baseline (t0) and longitudinally after the 10 rTMS sessions during the following month (D+15, M+1, M+3, M+6, M+12)

Visual Analogue Scale (Severity)/ Visual Analogue Scale (Frequency rate)

Secondary Outcome Measures
NameTimeMethod
MRI changesAssessed at baseline (t0) and 1 month after the rTMS sessions (M+1)

structural MRI/ functional MRI/ Diffusion Tensor Imaging/ MR-spectroscopy

Clinical StateAssessed at baseline (t0) and longitudinally after the 10 rTMS sessions during the following month (D+15, M+1, M+3, M+6, M+12)

Clinical Global Improvement \[CGI\]/ Positive \& Negative Symptoms Scale \[PANSS\]/ Global Assessment of Functioning \[GAF\].

For the auditory modality: Add the Auditory Hallucinations rating Scale \[AHRS\] frequency scale and total score/ Add the computerized Binary Scale of Auditory Speech Hallucinations \[cbSASH\]

Trial Locations

Locations (2)

Lille University Hospital Centre

🇫🇷

Lille, France

Saint-Anne Psychiatric Hospital

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath